Le glaucome primitif à angle ouvert

Bertaud, Samuel; Aragno, Vittoria; Baudouin, Christophe; Labbé, Antoine

doi:10.1016/j.revmed.2018.12.001

Cited by 42 publications

(38 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Progress is constantly being made in test administration, standardization, statistical evaluation, clinical analysis, and interpretation and prediction of the result based on the findings of the VF examination [ 51 , 52 ]. The only effective treatment to slow the progression of POAG is to reduce intraocular pressure (topical treatment, anti-glaucoma eye drops, and laser or surgical treatments), which acts on this main risk factor [ 53 ].…”

Section: Discussionmentioning

confidence: 99%

Aspects of Tertiary Prevention in Patients with Primary Open Angle Glaucoma

Munteanu

Roiu

et al. 2021

JPM

View full text Add to dashboard Cite

The purpose of the study is to assess the health of patients in the activity of tertiary prevention dedicated to preventing blindness caused by POAG (primary glaucoma with open angle and high tension) and NTG (primary glaucoma with open-angle and statistically normal tension—particular form of glaucoma with open angle) and preservation of the remaining visual function. The design of the study is epidemiological, observational, descriptive and retrospective, and uses only the data recorded in the existing records in the archives of the Ophthalmology office within the Integrated Outpatient Clinic of the Emergency Clinical Hospital of Oradea (IOCECHO) during the years 1999–2019 (anamnestic data; objective examination and paraclinical examination: intraocular pressure—IOP and visual field—VF). The methods of the study included the standardized protocol: anamnesis, physical ophthalmological examination, IOP determination, and computerized perimetry with the “Fast Threshold” strategy performed with the “Opto AP-300” perimeter. The obtained results were statistically processed with a specialized software (S.P.S.S.—I.B.M. Statistics version 22). The study examined the available data of 522 patients of which 140 were men (26.8%) and 382 were women (73.2%). The gender ratio was 0.37. In the period 1999–2019, 150,844 people with ophthalmic pathology were consulted in the Ophthalmology office of IOCECHO out of which 522 patients (0.35%) were diagnosed with primitive open-angle glaucoma, 184 people (35.2%) presented high IOP (POAG), and 338 people (64.8%) had statistically normal IOP (NTG). The annual proportion of cases diagnosed with glaucoma in the total number of patients examined was between 0.1% (2005; 2008; 2010) and 2.4% in 2012, when 101 people were detected. In the studied records, no cases of uni- and/or bilateral blindness were mentioned. The mean age of glaucoma patients at the first consultation was 60.81 ± 12.14 years with high frequencies in the 55–69 age groups and at the last consultation it was 66.10 ± 12.47 years with high frequencies in the age groups between 60–74 years. Monitoring and treatment of glaucoma patients was beneficial; IOP decreased statistically significantly: in patients with POAG by 46.16%, from 30.50 ± 7.98 mmHg to 16.42 ± 3.01 mmHg (p = 0.000) and in those with NTG by 17.44%, at 16.39 ± 3.66 mmHg at 13.53 ± 1.92 mmHG (p = 0.000). The duration of treatment and monitoring was on average 5.1 ± 3.4 years, for 184 patients (35.2%) with POAG and 5.1 ± 3.8 years for 338 patients (64.8%) with NTG. Tertiary prevention of glaucoma, by providing specialized care, ensures effective control of IOP and implicitly of the long-term evolution of the disease. IOP is the only modifiable risk factor in patients with POAG and NTG and its decrease prevents the progression of the disease and emphasizes the importance of early diagnosis and treatment. The management of the glaucoma patient consisted of: complete ophthalmological examination (subjective and objective), paraclinical examination with IOP, and VF measurement (valuable ophthalmological diagnostic tool) for disease detection and effective assessment of disease progression in order to improve the process of therapeutic decision making.

show abstract

Section: Discussionmentioning

confidence: 99%

Aspects of Tertiary Prevention in Patients with Primary Open Angle Glaucoma

Munteanu

Roiu

et al. 2021

JPM

View full text Add to dashboard Cite

show abstract

“…In our study, 12 eyes of 6 patients (7.50%) with monoclonal gammopathy had glaucoma, 10 eyes (6.25%) had open-angle glaucoma (OAG), and 2 eyes (1.25%) had angle-closure glaucoma (ACG). Bertaud et al [ 37 ] described the prevalence of OAG 3.05% in subjects between 40 and 80 years of age. Wright et al [ 38 ] described the prevalence of ACG 0.02% in subjects with 40–49 years of age, and ACG prevalence increases to 0.95% in subjects older than 70 years.…”

Section: Discussionmentioning

confidence: 99%

Ocular Signs and Ocular Comorbidities in Monoclonal Gammopathy: Analysis of 80 Subjects

Kormányos

Kovács

Németh

et al. 2021

Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose. To examine the ocular signs of monoclonal gammopathy and to evaluate ocular comorbidities in subjects with monoclonal gammopathy. Patients and Methods. We analyzed patients from two large referral hematology centers in Budapest, diagnosed and/or treated with monoclonal gammopathy between 1997 and 2020. As a control group, randomly selected individuals of the same age group, without hematological disease, have been included. There were 160 eyes of 80 patients (38.75% males; age 67.61 ± 10.48 (range: 38–85) years) with monoclonal gammopathy and 86 eyes of 43 control subjects (32.56% males; age 62.44 ± 11.89 (range 37–86) years). The hematological diagnosis was MGUS in 9 (11.25%), multiple myeloma in 61 (76.25%), smoldering myeloma in 6 (7.50%), and amyloidosis or Waldenström macroglobulinemia in 2 cases (2.50%–2.50%). Before detailed ophthalmic examination with fundoscopy, 42 subjects with gammopathy (52.50%) and all controls filled the Ocular Surface Disease Index (OSDI) questionnaire. Results. The OSDI score and best-corrected visual acuity (BCVA) were significantly worse in subjects with monoclonal gammopathy than in controls ( p = 0.02 ; p = 0.0005 ). Among gammopathy subjects, we observed potential corneal immunoglobulin deposition in 6 eyes of 4 (3.75%) patients. Ocular surface disease ( p = 0.0001 ), posterior cortical cataract ( p = 0.01 ), and cataract ( p = 0.0001 ) were significantly more common among gammopathy subjects than in controls (χ2 test). Conclusions. Ocular surface disease and cataract are more common, and BCVA is worse in patients with monoclonal gammopathy than in age-matched controls. Therefore, and due to the potential ocular signs and comorbidities of monoclonal gammopathy, we suggest a regular, yearly ophthalmic checkup of these patients to improve their quality of life.

show abstract

“…Glaucoma represents a heterogeneous group of chronically progressive neurodegenerative bilateral diseases of the optic nerve, clinically characterized by optical neuropathy, resulting in retinal ganglion cell death, optic nerve head cupping, and associated specific loss of the visual field [1][2][3]. The aetiology of the disease is considered to be multifactorial [4], while the clinical picture can differ, with a substantial risk of associated blindness, especially in adults over the age of 60 [5].…”

Section: Introductionmentioning

confidence: 99%

Psychopharmacological Treatment, Intraocular Pressure and the Risk of Glaucoma: A Review of Literature

Ciobanu

Dionisie

Neagu

et al. 2021

JCM

View full text Add to dashboard Cite

Through the years, the available psychopharmacological treatments have expanded with numerous new drugs. Besides weight gain, gastro-intestinal problems or Parkinson-like symptoms, ocular adverse effects of psychiatric drugs have been reported. These adverse effects are not common, but can be dangerous for the patient. This review summarises the current knowledge on the risk of raised intraocular pressure and glaucoma entailed by psychopharmacological treatment. Also, it provides updated data for clinicians involved in the treatment of patients with glaucoma or glaucoma risk factors. For this purpose, we performed an extensive literature search in the PubMed database using specific terms. Selective serotonin and noradrenaline reuptake inhibitors are the best evidenced as having no association with glaucoma. Antipsychotics, and especially first generation, seem to have no correlation with an increased intraocular pressure and therefore possibly with a risk of glaucoma, although a special attention should be paid when using ziprasidone. Tricyclic antidepressants, benzodiazepines and topiramate should be avoided in patients diagnosed with glaucoma or at risk. Clinicians should be aware of the possible psychotropic drug induced glaucoma and monitor at risk patients closely in order to prevent this condition. Irrespective of the psychopharmacological regimen taken into consideration, the glaucoma patient should be under the strict supervision of the ophthalmologist.

show abstract

Le glaucome primitif à angle ouvert

Cited by 42 publications

References 36 publications

Aspects of Tertiary Prevention in Patients with Primary Open Angle Glaucoma

Aspects of Tertiary Prevention in Patients with Primary Open Angle Glaucoma

Ocular Signs and Ocular Comorbidities in Monoclonal Gammopathy: Analysis of 80 Subjects

Psychopharmacological Treatment, Intraocular Pressure and the Risk of Glaucoma: A Review of Literature

Contact Info

Product

Resources

About